gilead glp-1 Stock Gains. It's Trying to Get Into the Obesity Drug Game Day Supply) Gilead Sciences | US News

10.1152/ajpgi.00035.2013 [DOI] [PubMed] [Google Scholar] 189.Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB

Some hypothetical explanations for the weaker anti-obesity response for both GLP-1 RAs in people with diabetes include the background medications that promote weight gain, the fear of hypoglycaemia inherently related to the treatment of diabetes, a decrease in glycosuria and subsequently less weight loss in diabetics, an altered microbiota in patients with obesity and diabetes and a genetic background that predispose to weight gain in patients with diabetes

doi: 10.1055/s-0031-1297042

Nevertheless, clinical translation remains hindered by several unresolved limitations